Advancing the Future of Peripheral Nerve Stimulation
OmniPNS™ is a division of SynerFuse® dedicated to advancing peripheral nerve stimulation. Built on Med-Ally EPG platform technology, OmniPNS™ leverages innovative engineering and research to develop next-generation solutions that address pain at the nerve.
Med-ally EPG Platform. Endless Potential.
Better technology begins with better platforms.
A division of SynerFuse®, Med-Ally is an engineering and product development innovator advancing a growing portfolio of External Pulse Generator (EPG) solutions.
Built on a patient-first approach, Med-Ally develops the platform technology that powers OmniPNS ULE™ and supports the future of peripheral nerve stimulation.
EPG Solutions with Ultra Low Energy™
OmniPNS ULE™ (Ultra Low Energy™) is our current development initiative. The device represents the merges Med-Ally EPG platform with ULE™ technology to advance peripheral nerve stimulation.
SynerFuse® is currently pursuing FDA 510(k) clearance for OmniPNS ULE™ and our Synerfuse® e-TLIF™ therapies.
focused on Clinical Development, Moving Toward comercialization
510(k) Pathway In Clinical Development
Expected Clearance 2027
LEADERSHIP
Justin Zenanko
CPA, MDiv
Chief Executive Officer of SynerFuse®
Nameer R. Haider
MD, FAAPM&R, DABPM
President of OmniPNS™
Chief Innovation Officer of SynerFuse®
Raja Edward Hitti
BSME, MEng, MBA
Chairman of the Board SynerFuse®, Chief Technology Officer of Med-Ally
Join Our Clinical Community
Are you a pain physician, neurologist, researcher, or healthcare partner interested in the future of peripheral nerve stimulation?
Register to:
Learn more about OmniPNS ULE™
Receive updates on clinical development
Participate in future webinars
Express interest in clinical trials